| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, excee...
Clear Street analyst Bill Maughan initiates coverage on WAVE Life Sciences (NASDAQ:WVE) with a Buy rating and announces Pric...
Wells Fargo analyst Tiago Fauth maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight and lowers the price target from...
Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production a...